Genomic abnormalities of tp53 define distinct risk groups of paediatric b-cell non-hodgkin lymphoma

HIGHLIGHTS

• who: Alexander M. Newman from the , mutational status was assessed using whole-exome sequencing (WES, n=90) or Sanger sequencing of exons , to , (n=5)WES data were generated using Illumina Nextera Exome enrichment (n=89) or TWIST Human Core Exome kit (n=1) and sequenced on an Illumina NovaSeq within the Newcastle University Genomics Core Facility or Illumina HiSeq by Eurofins Genomics (Germany). Data were analysed using the Genome Analysis Toolkit (GATK, .7) and variants called using Mutect2. PCR products for Sanger sequencing were amplified using primers designed for , (Supplementary Table, ) and sequenced by Eurofins Genomics . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.